期刊文献+

中药大品种科技竞争力报告(2018版)概要 被引量:12

Summary of Competitiveness Report on Science and Technology of Big Brand Traditional Chinese Medicine( 2018 Edition)
下载PDF
导出
摘要 当前,我国医药产业生态格局和行业运行规则正在剧变,中药产业面临新的挑战,以临床价值、科学价值为核心的科技创新驱动,成为中药产业高质量发展的关键推动力。科技竞争力集中体现了中成药产品的临床价值和科学价值,通过科技竞争力评价,有助于形成正确的价值导向,催生行业内生动力。项目组基于公开数据和评价模型,进行中药大品种科技竞争力评价,编制《中药大品种科技竞争力报告(2018版)》,全景式展示了中药大品种科技竞争力概况。本文包含全品类百强榜、非注射百强榜、各省区排行榜第一名、各治疗领域前三名等榜单。具有科技竞争力优势的中药大品种,正成为引领中药产业高质量发展的中坚力量。 At present,the ecological pattern and operation rules of the pharmaceutical industry in China are changing dramatically,the traditional Chinese medicine industry is facing new challenges.The scientific and technological innovation driven by clinical and scientific value has become the main driving force for the high-quality development of Chinese medicine industry.Scientific and technological competitiveness embodies the clinical and scientific value of Chinese patent medicine products.Through the evaluation of scientific and technological competitiveness,it is helpful to form the correct value orientation,and promote the endogenous power of the industry.Based on the open data and evaluation model,the project team carried out the evaluation of the scientific and technological competitiveness of large varieties of traditional Chinese medicine,and compiled the “Report on the Scientific and Technological Competitiveness of Large Varieties of Traditional Chinese Medicine(2018 Edition)”,which panoramically displayed the general situation of the scientific and technological competitiveness of large varieties of traditional Chinese medicine.The top 100 list of the whole category,the top 100 list of non-injection,the top one of the provinces and regions,and the top three of the treatment fields are included in this article.Large varieties of traditional Chinese medicine(TCM)with the advantage of scientific and technological competitiveness are becoming the backbone force leading the high-quality development of TCM industry.
作者 李耿 李振坤 郭宇博 程煜华 李文珊 刘立营 张秀梅 杨洪军 LI Geng;LI Zhen-kun;GUO Yu-bo;CHENG Yu-hua;LI Wen-shan;LIU Li-ying;ZHANG Xiu-mei;YANG Hong-jun(China Academy of Chinese Medical Sciences,Beijing 100070,China;Big Brand Traditional Chinese Medicine League,Beijing 100070,China;China Association of Chinese medicine,Beijing 100029,China;Institute of Scientific and Technical Information of China,Beijing 100038,China;Wanfang Data Co.,Ltd.,Beijing 100038,China;Institute of Chinese Materia Medica/China Academy of Chinese Medical Sciences,Beijing 100070,China)
出处 《中国现代中药》 CAS 2019年第1期1-19,共19页 Modern Chinese Medicine
基金 中国科协项目(2018-64) 国家中医药管理局项目(GZY-KJS-2018-016-09 GZY-FJS-2018-612)
关键词 中药大品种 科技竞争力 产品评价 大数据 评价模型 指标体系 科技因子 big brand traditional Chinese medicine scientific and technological competitiveness scientific and technological evaluation big data evaluation model evaluating indicator scientific factor score
  • 相关文献

参考文献4

二级参考文献28

  • 1杜丽华.关于药品不良反应与药害事件的思考[J].中国药房,2007,18(23):1761-1764. 被引量:16
  • 2中华人民共和国药品管理法[S].2001:7.
  • 3Xu H Y, Li K, Chen Y J, et al. Study on the absorbed finger- print-efficacy of Yuanhu Zhitong tablet based on chemical analysis, vasorelaxation evaluation and data mining[J]. PloS ONE, 2013, 8 (12) : e81135.
  • 4Xu H Y, Zhang Y C, Tao Y, et al. Study of chemical fingerprint for Yuanhu Zhitong tablet by UPLC/Q-TOF-MS[ J]. J Liq Chrom- atogr Relat Technol, 2013, 36:1.
  • 5Zhang Y C, Xu H Y, Chen X M, et al. Simultaneous quantifica- tion of 17 constituents from Yuanhu Zhitong tablet using rapid reso- lution liquid chromatography coupled with a triple quadrupole elec- trospray tandem mass spectrometry [ J ]. J Pharm Biomed Anal, 2011,56: 497.
  • 6郭宇博,张霄潇,杨洪军.产业环境分析和顶层设计的思考[N].中国中医药报,2014-4-18(7).
  • 7Ping YU. Rapid Cycle Evaluation : an Overview[ M]. Workshop of RCE in Institute of Policy and Management, CAS ,2014.
  • 8William Shrank. The Center for Medicare and Medicaid Innovation's Blueprint for Rapid - Cycle Evaluation of New Care and Pay- ment Models [ J ]. Health Affairs,2013,32 (4) : 1 - 6.
  • 9Scott Cody, Andrew Asher. Smarter, Better, Faster: the Potential for Predictive Analytics and Rapid -Cycle Evaluation to Improve Program Development and Outcomes [ M ]. The Hamilton Project, Brookings, 2014, ( 6 ), 147 - 155.
  • 10Jasanoff S. The Fifth Branch:Science Advisers as Policymakers [ M ]. Harvard University Press,2009.

共引文献50

同被引文献131

引证文献12

二级引证文献124

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部